Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5427-5434

  De Ioris, Maria Antonietta ^a   Contoli, Benedetta ^a   Jenkner, Alessandro ^a   De Pasquale, Maria Debora ^a   Serra, Annalisa ^a   De Sio, Luigi ^a   Pessolano, Rosanna ^a   Garganese, Maria Carmen ^a   Crocoli, Alessandro ^a   Corneli, Teresa ^a   Boldrini, Renata ^a   Castellano, Aurora ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Busulfan; Conditioning regimen; Neuroblastoma; Thiotepa

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; THIOTEPA; ANTINEOPLASTIC AGENT; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ADOLESCENT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLADDER DISEASE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DIARRHEA; FEMALE; HUMAN; LIVER TOXICITY; LUNG DISEASE; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROBLASTOMA; NEUROTOXICITY; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENE AMPLIFICATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RISK FACTOR;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GENE AMPLIFICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MELPHALAN; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RISK FACTORS; THIOTEPA; TRANSPLANTATION CONDITIONING;

EID: 84872515508     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Maris JM, Hogarty MD, Bagatell R and Cohn SL: Advances in the diagnosis and treatment of neuroblastoma. Lancet 369: 2106-2120, 2007.
2. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB and Reynolds CP: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165-1173,1999.
3. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T and Hero B: Myeloablative megatherapy with autologous stemcell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol 6: 649-658, 2005.
4. Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J and Jones DR: High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG- 1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 44: 348-357, 2005.
5. Matthay KK, Reynolds CP, Seeger RC and Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB and Villablanca JG: Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group study. J Clin Oncol 27: 1007-1013, 2009.
6. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C and Machin D: High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol 9: 247-256, 2008.
7. Fish JD, Grupp SA. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant 41: 159-165; 2008.
8. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K and Shamberger RC: High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 24: 2891-2896, 2006.
9. Grupp SA, Stern JW, Bunin N, Nancarrow C, Ross AA, Mogul M, Adams R, Grier HE, Gorlin JB, Shamberger R, Marcus K, Neuberg D, Weinstein HJ and Diller L: Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 18: 2567-2575, 2000.
10. Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M, Geissler G, Marymount MH, Liu D, Kalapurakal JA, Shore RM, Bardo DM, Schmoldt J, Rademaker AW and Cohn SL: Treatment of high-risk neuroblastoma with tripletandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 20: 2284-2292, 2002.
11. Philip T, Ladenstein R, Lasset C, Hartmann O, Zucker JM, Pinkerton R, Pearson AD, Klingebiel T, Garaventa A, Kremens B, Bernard JL, Rosti G and Chauvin F: 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 33: 2130-2135, 1997.
12. Flandin I, HartmannO, Michon J, Pinkerton R, Coze C, Stephan JL, Fourquet B, Valteau-Couanet D, Bergeron C, Philip T and Carrie C: Impact of TBI on late effects in children treated by megatherapy for stage IV neuroblastoma. A study for the French Society of Pediatric Oncology. Int J Radiat Oncol Biol Phys 64: 1424-1431, 2006.
13. Hobbie WL, Moshang T, Carlson CA, Goldmuntz E, Sacks N, Goldfarb SB, Grupp SA and Ginsberg JP: Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer 51: 679-683, 2008.
14. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R, Michon J, Pritchard J, Klingebiel T, Kremens B, Pearson A, Coze C, Paolucci P, Frappaz D, Gadner H and Chauvin F: Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumour Registry. J Clin Oncol 16: 953-965, 1998.
15. Hartmann O, Valteu-Couanet D, Vassal G, Lapierre V, Brugières L, Delgado R, Couanet D, Lumbroso J and Benhamou E: Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 23: 789-795, 1999.
16. Ladenstein R, Pötschger U, Hartman O, Pearson AD, Klingebiel T, Castel V, Yaniv I, Demirer T and Dini G; EBMT Paediatric Working Party. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant 41: S118-112, 2008.
17. De Ioris MA, Castellano A, Ilari I, Garganese MC, Natali G, Inserra A, De Vito R, Ravà L, De Pasquale MD, Locatelli F, Donfrancesco A and Jenkner A: Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma. Eur J Cancer 47: 572-578, 2011.
18. Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V, Couturier J, Darnfors C, Delattre O, Freeman-Edward J, Gambini C, Gross N, Hattinger CM, Luegmayr A, Lunec J, Martinsson T, Mazzocco K, Navarro S, Noguera R, O'Neill S, Potschger U, Rumpler S, Speleman F, Tonini GP, Valent A, Van Roy N, Amann G, De Bernardi B, Kogner P, Ladenstein R, Michon J, Pearson AD and Ambros PF: Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21: 2077-2084, 2003.
19. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M and Hedborg F: Revisions in the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 11: 1466-1477, 1993.
20. Kushner BH, Wolden S, LaQuaglia MP, Kramer K, Verbel D, Heller G and Cheung NK: Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 19: 821-2828, 2001.
21. Bearman SI, Appelbaum FR, Back A, Petersen FB, Buckner CD, Sullivan KM, Petersen FB, Buckner CD, Sullivan KM, Schoch HG, Fisher LD and Thomas ED: Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6: 1562-1568, 1988.
22. International Terminology Criteria for Adverse Events (CTCAE) Version 4. Available from URL: http://www.fda.gov/cder/cancer/toxicityframe.htm
23. Kaplan EL and Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1959.
24. Yalçin B, Kremer LC, Caron HN and van Dalen EC: High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev. 2010;5:CD006301.
25. Kasow KA, Stewart CF, Barfield RC, Wright NL, Li C, Srivastava DK, Leung W,Horwitz EM, Bowman LC, Handgretinger R and Hale GA: A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up. Bone Marrow Transplant. 2012 Mar 19. doi: 10.1038/bmt.2012.51.
26. Monnereau-Laborde S, Munzer C, Valteau-Couanet D, Ansoborlo S, Coze C, Chastagner P, Rubie H, Demeocq F, Stephan JL, Hartmann O and Perel Y: A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age. Pediatr Blood Cancer 57: 965-971, 2011.
27. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, Pulsipher M, Grupp SA and Diller L: Highrisk neuroblastoma treated with tandem autologous peripheralblood stem cell-supported transplantation: long-term survival update. J Clin Oncol 24: 2891-2896, 2006.
28. Matthay KK, Quach A, Huberty J. Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA and Maris JM: Iodine-131-- metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol 27: 1020-1025, 2009.
29. Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ, Singher LJ, Ettinger LJ, Gillespie A, Sam J and Poplack DG: Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49: 736-741, 1989.